CERTARA INC. DL-,01 Logo
US15687V1098
A2QJL8
CERT

CERTARA INC. DL-,01

Loading quotes...

Forecast

The analysts' average price target is €9.83 (-3.63%). The median is €10.89 (+6.76%).

Buy
  8
Hold
  9
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Certara misses Q2 forecast; stock falls about 16%

    Certara reported adjusted EPS of $0.08 for Q2 on revenue of $93.3 million, missing consensus estimates and sending the stock down about 16% in premarket trading. The software business grew moderately, while the services segment saw declines in revenue and bookings; adjusted EBITDA and margins fell slightly. Management confirmed full-year revenue and EPS targets, narrowed the EBITDA margin guidance to 29–31% and expects margin improvement from cost reductions; a $50 million share buyback program was approved. » More on de.investing.com


  • Certara: CFO John Gallagher resigns, interim CFO named and annual guidance confirmed

    Certara announces the resignation of Chief Financial Officer John Gallagher effective July 14, 2026. Faiz Mohammed will serve as interim CFO; the company has hired an executive search firm to find a permanent successor. Certara leaves its 2026 financial guidance unchanged; the stock had recently risen sharply and analysts still view the shares as potentially undervalued. » More on de.investing.com


  • Certara reorganizes around ACE and MID3, pushes AI integration and seeks $10M in cost cuts

    Certara announced a strategic realignment into two growth engines—ACE (accelerating clinical evidence) and MID3 (model-informed drug development and discovery)—to simplify operations and sharpen go-to-market execution. Management is embedding AI across products and internal functions, developing AI-native modules and a unifying data layer led by a new chief AI officer. The company targets about $10 million in cost reductions while maintaining R&D at roughly 10–11% of sales, and emphasizes scientist-to-scientist sales engagement and organic growth over near-term M&A. » More on finance.yahoo.com


  • Certara misses earnings forecast and stock tumbles after Q1 results

    Certara reported Q1 earnings per share of $0.09, missing the $0.11 estimate, while revenue of $106.9 million slightly beat expectations. After the results the stock fell about 19%, with market participants expressing concern over profitability and higher operating costs. The software segment grew 7%, while the services business shrank 4%. Management announced cost-control measures and investments in an AI-integrated platform; the outlook foresees a modest EPS increase in the coming quarters. » More on de.investing.com


  • Certara misses EPS, margin pressure drives stock down 17% premarket

    Certara reported Q1 revenue of $106.9m (+1%) and missed consensus with adjusted diluted EPS of $0.09 versus $0.11 expected. The company posted a net loss of $8.8m, adjusted EBITDA fell 9% to $31.7m and margins came under pressure, while software revenue rose (+7%) and services declined (-4%). Certara completed the sale of its regulatory and medical writing unit, reiterated its annual guidance and highlighted AI initiatives including the appointment of a chief AI officer and a partnership with NVIDIA, but investors remain wary due to profitability risks. » More on de.investing.com

Financials

In the last quarter, CERTARA INC. DL-,01 had revenue of €83.78M and net profit of €4.94M
(EUR) September 2026
YoY
Revenue 83.78M 6.02%
Gross profit 56.03M 1.31%
Net profit 4.94M 279.91%
EBITDA 17.81M 10.56%

Fundamentals

Metric Value
Market capitalization
€1.6B
Number of shares
152.54M
52-week high/low
€11.44 - €4.04
Dividends No
Beta
1.30
P/E ratio
-28.02
PEG ratio
0.07
P/B ratio
1.81
P/S ratio
4.43

Company profile

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Name
CERTARA INC. DL-,01
CEO
Jon Resnick
Headquarters Radnor, pa
USA
Website
Sector
Health Care
Industry
Health Care Technology
IPO
12/11/2020
Employees 1,546

Ticker symbols

Exchange Symbol
NASDAQ
CERT
Hamburg
700.HM
🍪

Parqet  uses cookies. Learn more